Icon
+91 94997 68112
Login Register

RESTASIS - (0.05% Emulsion:Opthalmic)

CYCLOSPORINE Abbvie
0.05% Emulsion:Opthalmic
More Than $1000 mn
Less Than 5
More Than 5
More Than 5
 None
Less Than 5
 None
Increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.
Yes
****, ******, *****, ***** **** ** ** *** *** *** ******* ‘***, ‘***, ‘***, ‘***, *** ‘*** *** ******** ** *** **, ****. ******** ******** * **** ***** ** **** ***** **** *** **********. **** ** *** **** ******** ****** ********* ******** ***** ** ******* ***** *********** ** *********. ***** ******** ***** * **** ******* *********, *** ****** *** **** ******(**** ******) ** *** ********* ***** * **** ** **** *** **** ******* ** *** ****. ** ********** ******* ****, ***** & ***** ***** ***** ******* '***; '***; '*** *** '*** ** *******, *** ***** ********* **** ******* * ******** *** ** *** **** ****** '*** & '*** . ******** ******** *** ** ********* ** ******* *******. ********** ********* **** *** ****** & **** ******(**** ******) **** ******* '*** & '***. ************, ******** ******* * ********** **** ********** (******) ******* *** ********** ** ********* *** ** ******** ********** ** ****** *** ******* ** ******** **, ****, ** ******* ***** ******* *************. ************, ***** ******* *************, ******** **** ****** *** ********* ********** ** ****** ** ********** ******* ******* ** ********® ** ****** **, ****. ******* ******** ***** * **** ******* ****** & ******** ** ***** ********* ***** **** ** **** ******* '***, '***. ******* ******* ******* *** ** ******** *** **** ***. ** ******* ******* ******* ******** ***** ******** **** *** *** ******** **** *** ****** ** ******** *** ****** *** *******. ** *** ******* ** ******* ********** ******** ** **** *** *** ***********. ** ** ********** **** ******** *********** *** ******* ****** ** ***** ***** ****** ***** (****** ******** *****) ** ***** ** ***** *** ********** ** ****. *** ***** **** ******* $**.** ******* ** ***** *** ** ** $** ******* ******** ** **** ** *** ****.
RESTASIS Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
**** ******* ******* ******* ******* ******* *******
****** ******* ******* ******* ******* ******* *******
***** ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ** *** **, **** ******* ******** *** ****** *******
****** *** \ ** *** **, **** ******* ******** *** ****** *******
***** *** \ ** *** **, **** ******* **** ****** *** **, ****
  1. *** **, **** : ****, ******, *****, ***** ***** **** ** **** ******* ‘***, ‘***, ‘***, ‘***, *** ‘*** *** ******** ** *** **, ****.
  2. *** **, **** : ******** ***** * **** ******* ****, ******, *****, ***** ** ******** ***** ** ******* ******** ** ***** ******** ********.
  3. *** *, **** : ******** ***** * **** ******* ********* ** ******* ******** ** ***** ******** ******** ** ********* ***** **** ** **** ******* ‘***, ‘***, ‘***, ‘***, *** ‘*** *** ******** ** *** **, ****.
  4. *** **, **** : ******** ***** * **** ******* ***** (**** ****) ** *** ******* ******* ***** **** ** **** ****** '*** *** **, ****.
  5. *** **, **** : ******** ***** * **** ******* *** ****** ** *** ***** **** ** **** ******* ‘***, ‘***, ‘***, ‘***, *** ‘*** *** ******** ** *** **, ****.
  6. *** *, **** : *****'* **** *********** *** *********** ****** ‘***, ‘***, ‘***, ‘***, *** ‘*** *** ******** ** *** **, **** *** ******** ***** ******* ** ******** ** ******.
  7. *** **, **** : ******** ***** * **** ******* **** ******(**** ******) ** **** ***** **** ** **** ******* ‘***, ‘***, ‘***, ‘***, *** ‘*** *** ******** ** *** **, ****.
  8. *** **, **** : ******** ******* **** **** ****. ********* ** ********** **** **** *** ****** ******* ** *** **, ****
  9. *** **, **** : *** ** ***** ** ***** ** ****, ***** & ***** ********* **** ******* *,***,***; *,***,***; *,***,*** *** *,***,*** *** ******* *** ********* ******** * ******** *** ** *** *** *** ********* *** *******.
  10. *** **, **** : ******** ******** *** ** ********* ** ******* *******.
  11. *** **, **** : ******** ******* * ********** **** ******, *** *** ********** . ********* ** ********** **** *** ****** ******* ******** ** ******** **, ****, ** ******* ***** ******* *************.
  12. *** **, **** : ******** ***** * **** ******* ******** ****** ** ******** ***** **** ** **** ******* ‘***, ‘***, ‘***, ‘***, *** ‘*** *** ******** ** *** **, ****.
  13. *** **, **** : ******** ***** * **** ******* ****** ** ****** ***** **** ** **** ******* ‘***, ‘***, ‘***, ‘***, *** ‘*** *** ******** ** *** **, ****.
  14. *** *, **** : ********** *** ********* **** ******** ****** & *** ***** ** ********* *** *******.
  15. *** *, **** : ********** *** ********* **** ****** ****** & *** ***** ** ********* *** *******.
  16. *** **, **** : ********** *** ********* **** ********** & *** ***** ** ********* *** *******.
  17. *** **, **** : **** ***** **** '*** ****** ** *******.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.